The embodiments relate to a pharmaceutically effective composition comprising sustained release particles, each sustained release particle comprising a shell and a core, wherein the shell comprises a first material and a second material, the second material comprising a first biodegradable material, wherein the core is enclosed by the shell and the core comprises a drug, wherein the first material is distributed in a matrix of the first biodegradable material, wherein the first material is configured to create holes in the shell and comprises metallic particles, wherein the holes allow the drug to be released to the exterior of the shell through the holes, and wherein the drug comprises a targeting material or targeting molecule that binds to a certain organ, object or a specific site within a body of a human or an animal.

Sustained release pharmaceutical compositions comprising a therapeutically effective amount of pyridostigmine or a pharmaceutically acceptable salt thereof, a diluent, and a copolymer comprising polyvinyl acetate and polyvinylpyrrolidone, wherein the compositions are produced by hot-melt extrusion.

he invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.

The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

A method for producing Metal Organic Framework (MOF) having a framework that encapsulates a bio-molecule, the method comprising combining in a solution the bio-molecule and MOF precursors, wherein the bio-molecule promotes formation of the encapsulating framework. The method stems from a surprising effect that a bio-molecule can promote or trigger the formation of MOF when combined together in a solution with MOF precursors. That is, it has now been found that a bio-molecule can effectively act as a seed around which the framework forms, with the resulting framework encapsulating the bio-molecule.

The invention is directed to a particle containing at least a volatile substance comprising a core comprising at least one matrix material and the at least one volatile substance and at least one coating layer, whereby a first coating layer is a non-confluent layer comprising at least a carrier material, whereby optionally the non-confluent layer contains at least one hydrophobic substance, and optionally the particle is surrounded by at least one confluent layer and/or further non-confluent layer(s) as well as to a process for producing the same.

A process for producing a solid dispersion of a material by spraying the material onto a fluidized cloud of carrier particles in a fluid bed. The fluidized cloud of carrier particles is formed by adding a solid or liquid carrier to a fluid bed. The material to be sprayed is in a liquid or gas form. The process is especially applicable to the formation of amorphous solid powder pharmaceutical ingredients.

The present invention relates generally to recombinant adenoviral pharmaceutical formulations. More particularly, the present invention relates to SiO.sub.2-gel-based controlled release recombinant adenoviral pharmaceutical formulations.

The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced C.sub.max, a C.sub.min:C.sub.max ratio of 0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.